Novartis pays Synnovation $2B upfront for breast cancer program as rivals circle Read more →

Gilead turns down chance to build on Assembly's phase 1-stage HBV antiviral Read more →

Embecta to buy auto-injector maker Owen Mumford for $200M to diversify beyond insulin Read more →